InMed Pharmaceuticals Inc. (INM )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol INM
- Company InMed Pharmaceuticals Inc.
- Price $1.6
- Changes Percentage 135.05
- Change 0.9193
- Day Low $1.31
- Day High $1.79
- Year High $7.98
- Year Low $0.58
- Market Cap $2,895,882
- Price Avg 50 EMA (D) $0.72
- Price Avg 200 EMA (D) $1.4
- Exchange NASDAQ
- Volume 91,540,480
- Average Volume 97,980
- Open $1.79
- Previous Close $0.68
- EPS -1.47
- PE -1.09
- Earnings Announcement 2026-09-18 12:00:00
- Shares Outstanding $1,809,926
Company brief: INMED PHARMACEUTICALS INC. (INM )
- Healthcare
- Biotechnology
- Mr. Eric A. Adams B.S. Chem., M.I.B.
- https://www.inmedpharma.com
- CA
- N/A
- 05-05-2014
- CA4576376012
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
INM Corporation News
INM Stock Alert: Halper Sadeh LLC is Investigating Whether InMed Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
businesswire.com -- NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of InMed Pharmaceuticals, Inc. (NASDAQ: INM) and Mentari Therapeutics, Inc. Upon closing of the pr...
Penny Stock InMed Pharmaceuticals Merger Deal Targets Migraine Pipeline
benzinga.com -- InMed Pharmaceuticals Inc. (NASDAQ:INM) shares are up during Tuesday's premarket session, as the company announced a merger agreement with Mentari Therapeutics....
InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies
prnewswire.com -- Mentari's parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapies Concurrent oversubs...
InMed Pharmaceuticals Amends Preferred Investment Options
newsfilecorp.com -- Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of propr...